

NLM Citation: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Florbetapir F

18. [Updated 2019 Jun 30].

Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/



Florbetapir F 18

Revised: June 30, 2019.

CASRN: 56103-76-7

Drug Levels and Effects

Summary of Use during Lactation

Information in this record refers to the use of florbetapir 18 as a diagnostic agent. No information is available on the use of florbetapir 18 during breastfeeding. The manufacturer recommends withholding breastfeeding for 24 hours after a diagnostic dose of 370 MBq (10 mCi). This length of time is greater than 10 half-lives of the radioisotope, so the nursing infant should not be exposed to radiation if this guideline is followed. The mother can nurse just before administration of the radiopharmaceutical. If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[1][2][3]

Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[4]

Drug Levels

Fluorine F18 decays by positron emission with a physical half-life of 109.7 minutes.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Howe DB, Beardsley M, Bakhsh S. Appendix U. Model procedure for release of patients or human research subjects administered radioactive materials. In, NUREG-1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. U.S. Nuclear Regulatory

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

Commission Office of Nuclear Material Safety and Safeguards. 2008;9, Rev. 2. Available at: http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/

- 2. Mountford PJ, Coakley AJ. A review of the secretion of radioactivity in human breast milk: data, quantitative analysis and recommendations. Nucl Med Commun. 1989;10:15-27. PubMed PMID: 2645546.
- 3. Early PJ, Sodee DB. Principles and practice of nuclear medicine. 2nd ed. St. Louis. Mosby-Year Book, Inc. 1995:1380-1.
- 4. Stabin MG, Breitz HB. Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. J Nucl Med. 2000;41:863-73. PubMed PMID: 10809203.

Substance Identification

Substance Name

Florbetapir F 18

CAS Registry Number

56103-76-7

Drug Class

Breast Feeding

Lactation

Radiopharmaceuticals

Fluorine Radioisotopes

Diagnostic Agents